Rituximab as first‐line treatment for the management of adult patients with non‐severe hemophilia A and inhibitors

The role of immunosuppression in the management of patients with congenital hemophilia and inhibitors is uncertain. The use of rituximab has been limited to case reports and case series. In most reports, rituximab was used as second‐line or third‐line treatment following failure of conventional immune tolerance induction therapy, and more commonly in pediatric patients.

[1]  J. Astermark,et al.  GENERAL INTRODUCTION AND OUTLINE OF THE THESIS , 2012 .

[2]  K. McDonagh,et al.  The Reversal of Inhibitors in Congenital Hemophilia , 2013, Pharmacotherapy.

[3]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  C. Kempton,et al.  Eradication of factor viii inhibitors in patients with mild and moderate hemophilia A , 2012, American journal of hematology.

[5]  K. Peerlinck,et al.  Mild haemophilia: a disease with many faces and many unexpected pitfalls , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  G. Lippi,et al.  Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  G. Aprili,et al.  Inhibitors in mild/moderate haemophilia A: two case reports and a literature review. , 2008, Blood transfusion = Trasfusione del sangue.

[8]  E. Santagostino,et al.  International workshop on immune tolerance induction: consensus recommendations 1 , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  R. Lindeman,et al.  Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  V. Blanchette,et al.  Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  P. Moreau,et al.  Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors. , 2006, Seminars in hematology.

[12]  S. Paisley,et al.  The epidemiology of inhibitors in haemophilia A: a systematic review , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  J. Voorberg,et al.  Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618→Ser mutation responsive to immune tolerance induction and cyclophosphamide , 2002, British journal of haematology.

[14]  R. Kulkarni,et al.  Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy , 2001, American journal of hematology.

[15]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[16]  R. Bagnall,et al.  Factor VIII inhibitors in mild and moderate‐severity haemophilia A , 1998, Thrombosis and haemostasis.

[17]  R. Bagnall,et al.  Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A , 1998, Thrombosis and Haemostasis.